Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin
- PMID: 15564564
- DOI: 10.1161/01.RES.0000149165.99974.12
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin
Abstract
Vascular calcification often occurs with advancing age, atherosclerosis, various metabolic disorders such as diabetes mellitus and end-stage renal disease, or in rare genetic diseases, leading to serious clinical consequences. Such mineralization can occur at various sites (cardiac valves, arterial intima or media, capillaries), involve localized or diffuse widespread calcification, and result from numerous causes that provoke active inflammatory and osteogenic processes or disordered mineral homeostasis. Although valuable research has defined many key factors and cell types involved, surprising new insights continue to arise that deepen our understanding and suggest novel research directions or strategies for clinical intervention in calcific vasculopathies. One emerging area in vascular biology involves the RANKL/RANK/OPG system, molecules of the tumor necrosis factor-related family recently discovered to be critical regulators of immune and skeletal biology. Evidence is accumulating that such signals may be expressed, regulated, and function in vascular physiology and pathology in unique ways to promote endothelial cell survival, angiogenesis, monocyte or endothelial cell recruitment, and smooth muscle cell osteogenesis and calcification. Concerted research efforts are greatly needed to understand these potential roles, clarify whether RANKL (receptor activator of nuclear factor kappaB ligand) promotes and osteoprotegerin (OPG) protects against vascular calcification, define how OPG genetic polymorphisms relate to cardiovascular disease, and learn whether elevated serum OPG levels reflect endothelial dysfunction in patients. Overall, the RANKL/RANK/OPG system may mediate important and complex links between the vascular, skeletal, and immune systems. Thus, these molecules may play a central role in regulating the development of vascular calcification coincident with declines in skeletal mineralization with age, osteoporosis, or disease.
Similar articles
-
Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.Calcif Tissue Int. 2004 Jan;74(1):103-6. doi: 10.1007/s00223-003-0011-y. Epub 2003 Oct 6. Calcif Tissue Int. 2004. PMID: 14523602 Review.
-
Osteoclast precursors, RANKL/RANK, and immunology.Immunol Rev. 2005 Dec;208:19-29. doi: 10.1111/j.0105-2896.2005.00336.x. Immunol Rev. 2005. PMID: 16313338 Review.
-
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. doi: 10.1016/j.cytogfr.2004.06.004. Cytokine Growth Factor Rev. 2004. PMID: 15561602 Review.
-
[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].Clin Calcium. 2005 Jan;15(1):35-42. Clin Calcium. 2005. PMID: 15632471 Review. Japanese.
-
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.Expert Rev Cardiovasc Ther. 2006 Nov;4(6):801-11. doi: 10.1586/14779072.4.6.801. Expert Rev Cardiovasc Ther. 2006. PMID: 17173497 Review.
Cited by
-
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.Nat Med. 2013 Mar;19(3):358-63. doi: 10.1038/nm.3084. Epub 2013 Feb 10. Nat Med. 2013. PMID: 23396210
-
Calcium intake is not associated with increased coronary artery calcification: the Framingham Study.Am J Clin Nutr. 2012 Dec;96(6):1274-80. doi: 10.3945/ajcn.112.044230. Epub 2012 Nov 7. Am J Clin Nutr. 2012. PMID: 23134889 Free PMC article.
-
Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.Int J Mol Sci. 2020 Sep 18;21(18):6846. doi: 10.3390/ijms21186846. Int J Mol Sci. 2020. PMID: 32961953 Free PMC article.
-
Association of circulating sclerostin with vascular calcification in Afro-Caribbean men.Atherosclerosis. 2015 Mar;239(1):218-23. doi: 10.1016/j.atherosclerosis.2015.01.010. Epub 2015 Jan 17. Atherosclerosis. 2015. PMID: 25618029 Free PMC article.
-
Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: role of myofibroblasts in vascular calcification.Am J Pathol. 2007 Jul;171(1):116-23. doi: 10.2353/ajpath.2007.060930. Am J Pathol. 2007. PMID: 17591959 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases